10:49 AM EDT, 05/21/2024 (MT Newswires) -- Sona Nanotech ( SNANF ) said Tuesday it has appointed Dr. Carman Giacomantonio M.D. as Chief Medical Officer. A practicing surgical oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University, Dr. Giacomantonio leads a productive translational research group at the university and has successfully initiated two clinical trials in cancer immunotherapy. He currently serves on Sona's Advisory Board and is the Principal Investigator for Sona's pre-clinical studies using the company's gold nanorods in its Targeted Hyperthermia Therapy (THT) for triple negative breast cancer, melanoma, and colorectal cancer.

The company has also filed a U.S. provisional patent application regarding a gold nanorod conjugation concept for targeted drug delivery and deployment applications in the medical field. Sona intends to convert the filing to an international patent application and/or regular patent applications in various countries, including the U.S., over the next year.